Biodexa Pharmaceuticals (BDRX) Change in Cash (2015 - 2022)

Biodexa Pharmaceuticals (BDRX) has 5 years of Change in Cash data on file, last reported at -$4.3 million in Q4 2022.

• For the quarter ending Q4 2022, Change in Cash rose 5.22% year-over-year to -$4.3 million; the trailing twelve-month figure through Dec 2022 stood at -$17.9 million (up 32.88% YoY), and the FY2025 full-year result was $9.1 million, up 263.93% from the prior year.
• Change in Cash grew to -$4.3 million in Q4 2022, from -$4.5 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $8.6 million in Q4 2019 to a low of -$9.0 million in Q4 2020.
• A 4-year average of -$3.8 million and a median of -$4.5 million in 2021 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash slumped 204.11% in 2020 and soared 49.85% in 2021, its largest moves.
• Tracing BDRX's Change in Cash over 4 years: stood at $8.6 million in 2019, then sank by 204.11% to -$9.0 million in 2020, then jumped by 49.85% to -$4.5 million in 2021, then grew by 5.22% to -$4.3 million in 2022.
• Business Quant data shows BDRX's Change in Cash at -$4.3 million in Q4 2022, -$4.5 million in Q3 2022, and -$4.5 million in Q4 2021.